Imugene Ltd announced a second complete response in its Phase 1b azer-cel trial targeting patients with mantle cell lymphoma (MCL) who had failed prior BTKi therapy. The patient showed complete tumor shrinkage by Day 28, earlier than expected, highlighting a promising treatment for this aggressive cancer. CEO Leslie Chong emphasized that azer-cel helps restore effectiveness of BTKi drugs, potentially extending patient benefits. The company is advancing enrollment and discussions with pharmaceutical partners to accelerate development and registration.
Bitcoin faces pressure even as the U.S. Dollar Index weakens and rate hike bets fade, due to record outflows from spot Bitcoin ETFs totaling $4.0 to $4.5 billion in June. A softer dollar typically supports Bitcoin by improving global purchasing power...
Revolut will remove Tether's USDT stablecoin from its platform by August 31, 2026, disabling purchases from July 6. This move aligns with regulatory and risk considerations under the EU's new Markets in Crypto-Assets (MiCA) rules, which have led othe...
XRP price has rebounded to around $1.145, showing a 4% gain in 24 hours, after forming a double bottom near $1.05 and $1.0092, which suggests sellers may be losing control. The key level to watch is the $1.28 to $1.29 neckline; a daily close above th...
Revolut, a major European fintech platform, will stop supporting Tether (USDT) stablecoin by August 31, 2026. Users can buy USDT until July 6 and deposit until July 30, but after August 31, remaining USDT balances will convert to fiat currency. This ...
Ripple's XRP Ledger (XRPL) has been working on quantum-resistant security solutions since 2024 to safeguard against future quantum computing risks. This proactive approach uses a hybrid signature framework combining current cryptography with quantum-...
